Saturn V Capital Management LLC
Saturn V Capital Management LLC is a San Francisco-based investment adviser and asset manager founded in 2022. The firm is registered with the SEC and primarily manages equity portfolios for institutional and accredited clients. Its operations are compact, with approximately 4 employees, three-quarters of whom are investment professionals. Saturn V specializes in providing asset management solutions to sophisticated investors.
Investment Strategy
Saturn V Capital Management pursues a fundamental, research-driven investment philosophy focused on U.S. equities, with an emphasis on identifying long and short opportunities primarily in the healthcare and biotech sectors. The firm manages concentrated portfolios, relying on deep sector expertise, bottom-up security analysis, and risk management to deliver returns while adapting to market dynamics. The approach is rooted in value-oriented analysis and disciplined portfolio construction.
Latest 13F Filing Activity
Saturn V Capital Management LLC filed their most recent 13F report on Jun 30, 2025 disclosing 24 equity positions with a total 13F market value of $247M. The fund increased holdings in Jazz Pharmaceuticals PLC, Dyne Therapeutics Inc., Amylyx Pharmaceuticals Inc. among other positions. Saturn V Capital Management LLC reduced exposure to Ascendis Pharma A/s, Syndax Pharmaceuticals Inc., Disc Medicine Inc. among others.
Top Holdings
Equity Positions (24)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
J JAZZ | JAZZ PHARMACEUTICALS PLC | 8.90% | $22.0M | 206,952 | $106.12 | $106.12 | +$22.0M |
I IRON | DISC MEDICINE INC | 8.50% | $21.0M | 396,115 | $43.49 | $52.96 | -$4.7M |
A AMLX | AMYLYX PHARMACEUTICALS INC | 8.47% | $20.9M | 3,260,570 | $4.34 | $6.41 | +$12.3M |
P PCVX | VAXCYTE INC | 7.17% | $17.7M | 544,221 | $46.17 | $32.51 | +$8.9M |
C COGT | COGENT BIOSCIENCES INC | 6.69% | $16.5M | 2,297,524 | $8.31 | $7.18 | +$7.6M |